Legal Representation
Attorney
Brent R. Bellows
USPTO Deadlines
Application History
9 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 5, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| May 5, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| May 5, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Oct 21, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 21, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 21, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 12, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 13, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 10, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Research and development in the field of gene therapy, namely, the research and development of gene therapy pharmaceutical compositions for use in treating genetic disorders in human patients by targeting gene insertion into the liver
First Use Anywhere:
Sep 9, 2021
First Use in Commerce:
Sep 9, 2021
Classification
International Classes
042